A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response

Li H., et al.
JCI Insight
September 2020
Authors and Affiliates
Hao-Dong Li 1, Changzheng Lu 1, He Zhang 2, Qing Hu 1, Junqiu Zhang 3, Ileana C. Cuevas 1, Subhransu S. Sahoo 1, Mitzi Aguilar 1, Elizabeth G. Maurais 1, Shanrong Zhang 4, Xiaojing Wang 4, Esra A. Akbay 1,5, Guo-Min Li 3,4, Bo Li 5,6,7, Prasad Koduru 1, Peter Ly 1,5,8, Yang-Xin Fu 1,5,7, and Diego H. Castrillon 1,5,9; 1 Department of Pathology, 2 Quantitative Biomedical Research Center, Department of Population and Data Sciences, 3 Department of Radiation Oncology, 4 Advanced Imaging Research Center, 5 Simmons Comprehensive Cancer Center, 6 Lyda Hill Department of Bioinformatics, 7 Department of Immunology, 8 Department of Cell Biology, and 9 Department of Obstetrics & Gynecology, UT Southwestern Medical Center, Dallas, Texas, USA.

The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma

Premal DL., et al.
Science Translational Medicine
September 2020
Authors and Affiliates
Premal D Lulla 1, Ifigeneia Tzannou 2, Spyridoula Vasileiou 2, George Carrum 2, Carlos A Ramos 2, Rammurti Kamble 2, Tao Wang 2, Mengfen Wu 2, Mrinalini Bilgi 2, Adrian P Gee 2, Shivani Mukhi 2, Betty Chung 2, Linghua Wang 2, Ayumi Watanabe 2, Manik Kuvalekar 2, Mira Jeong 2, Yumei Li 2, Shamika Ketkar 2, Matthew French-Kim 2, Bambi Grilley 2, Malcolm K Brenner 2, Helen E Heslop 2, Juan F Vera 2, Ann M Leen 2; 1 Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX 77030, USA 2 Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX 77030, USA

The Proximal Airway Is a Reservoir for Adaptive Immunologic Memory in Idiopathic Subglottic Stenosis

Gelbard A., et al.
September 2020
Authors and Affiliates
Alexander Gelbard 1, Celestine Wanjalla 2, Christopher T Wootten 1, Wonder P Drake 2, Anne S Lowery 1, David A Wheeler 3, Maria F Cardenas 3, Andrew G Sikora 4, Ravi R Pathak 4, Wyatt McDonnell 5, Simon Mallal 2, Mark Pilkinton 2; 1 Department of Otolaryngology-Head & Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, U.S.A. 2 Department of Medicine, Division of Infectious Disease, Vanderbilt University Medical Center, Nashville, Tennessee, U.S.A. 3 Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, U.S.A. 4 Bobby R. Alford Department of Otolaryngology-Head & Neck Surgery, Baylor College of Medicine, Houston, Texas, U.S.A. 5 10x Genomics Inc, Pleasanton, California, U.S.A.

Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine

Rumfield et al.
Journal for ImmunoTherapy of Cancer
June 2020
Authors and Affiliates
Claire Smalley Rumfield, Samuel T Pellom, Y Maurice Morillon II, Jeffrey Schlom and Caroline Jochems; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA Correspondence to Dr Jeffrey Schlom; schlomj@mail.nih.gov

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

Algazi et al.
Clinical Cancer Research
June 2020
Authors and Affiliates
Alain P Algazi # 1, Christopher G Twitty # 2, Katy K Tsai 1, Mai Le 3, Robert Pierce 4, Erica Browning 2, Reneta Hermiz 2, David A Canton 2, Donna Bannavong 2, Arielle Oglesby 1, Murray Francisco 2, Lawrence Fong 1, Mikael J Pittet 5, Sean P Arlauckas 6, Christopher Garris 7, Lauren P Levine 1, Carlos Bifulco 8, Carmen Ballesteros-Merino 8, Shailender Bhatia 4, Sharron Gargosky 2, Robert H I Andtbacka 9, Bernard A Fox 8, Michael D Rosenblum 1, Adil I Daud 10; 1University of California, San Francisco, San Francisco, California. 2OncoSec Medical Incorporated, Pennington, New Jersey. 3DR HOPE LLC, Seattle, Washington. 4Fred Hutchinson Cancer Research Center, Seattle, Washington. 5Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 6Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 7Rockefeller University, New York, New York. 8Earle A. Chiles Research Institute, Portland, Oregon. 9Huntsman Cancer Institute, Salt Lake City, Utah. 10University of California, San Francisco, San Francisco, California. Adil.daud@ucsf.edu. #Contributed equally.

A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors

Yamauchi et al.
bioRxiv
June 2020
Authors and Affiliates
Takayoshi Yamauchi1 , Toshifumi Hoki1 , Takaaki Oba1 , Vaibhav Jain1 , Hongbin Chen1, Kristopher Attwood4 , Sebastiano Battaglia1,5, Saby George2,3, Gurkamal Chatta2 , Igor Puzanov2, Carl Morrison6 , Kunle Odunsi1,7,8, Brahm H. Segal2,3,8, Grace K. Dy2, Marc S. Ernstoff2,3 , Fumito Ito1,8,9,10* Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY 2 Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York 3 Department of Medicine, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, the State University of New York, Buffalo, NY 4 Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 5 Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 6 Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 7 Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 8 Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 9 Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 10 Department of Surgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, the State University of New York, Buffalo, NY

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Gauthier J, et al.
Blood
May 2020
Authors and Affiliates
Jordan Gauthier,1-3 Alexandre V. Hirayama,1,3 Janaki Purushe,1 Kevin A. Hay,1,4 James Lymp,5 Daniel H. Li,5 Cecilia C. S. Yeung,1,6 Alyssa Sheih,1 Barbara S. Pender,1 Reed M. Hawkins,1 Aesha Vakil,1 Tinh-Doan Phi,1 Rachel N. Steinmetz,1 Mazyar Shadman,1,2 Stanley R. Riddell,1-3 David G. Maloney,1-3 and Cameron J. Turtle1-3 1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; 2Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; 3Integrated Immunotherapy Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA; 4Department of Medicine, University of British Columbia, Vancouver, BC, Canada; 5Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA; and 6Department of Pathology, University of Washington, Seattle, WA

Genetic and Immune Changes Associated with Disease Progression under the Pressure of Oncolytic Therapy in A Neuroblastoma Outlier Patient

Franco-Luzon et al.
Cancers
April 2020
Authors and Affiliates
Lidia Franco-Luzón 1, Sandra García-Mulero 2 3, Rebeca Sanz-Pamplona 3, Gustavo Melen 4 5, David Ruano 5, Álvaro Lassaletta 5, Luís Madero 1 5 6, África González-Murillo 4 5, Manuel Ramírez 4 5; 1Children Oncohematology Foundation, 28079 Madrid, Spain. 2Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain. 3Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) and CIBERESP, L'Hospitalet de Llobregat, 08908 Barcelona, Spain. 4Biomedical Research Foundation, Niño Jesús Children Hospital, 28009 Madrid, Spain. 5La Princesa Institute of Health Research, 28006 Madrid, Spain. 6Oncohematology Unit, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.